Effects of basic fibroblastic growth factor on the growth of human medulloblastoma xenografts

Journal of Neuro-Oncology

Volumn 67, Issue 1-2, 2004, Pages 139-146

  Vachon, Pascal ^a   Girard, Christiane ^a   Théorêt, Yves ^b  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b UNIVERSITY OF MONTREAL   (Canada)

Author keywords

Basic fibroblastic growth factor; Medulloblastoma; Nude mice; Xenograft

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR; BUFFER; DRUG VEHICLE; PHOSPHATE; SODIUM CHLORIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN TISSUE; CANCER CHEMOTHERAPY; CELL DIFFERENTIATION; CELL NUCLEUS; CELL SUSPENSION; CLINICAL PROTOCOL; CONTROLLED STUDY; CYTOPLASM; DRUG DOSE REGIMEN; DRUG INDICATION; EUCHROMATIN; GENERAL ANESTHESIA; HISTOPATHOLOGY; HUMAN; HUMAN CELL; INJECTION SITE; INOCULATION; MEDULLOBLASTOMA; MOUSE; NONHUMAN; NUDE MOUSE; PUTAMEN; RIGHT HEMISPHERE; STATISTICAL SIGNIFICANCE; STEREOTAXIS; TUMOR CELL LINE; TUMOR GROWTH; TUMOR VOLUME; TUMOR XENOGRAFT;

ANIMALS; CELL DIVISION; CELL LINE, TUMOR; CELL SURVIVAL; FIBROBLAST GROWTH FACTOR 2; HUMANS; INJECTIONS, INTRAVENTRICULAR; MEDULLOBLASTOMA; MICE; MICE, NUDE; NEOPLASMS, EXPERIMENTAL; TRANSPLANTATION, HETEROLOGOUS;

EID: 1842589287     PISSN: 0167594X     EISSN: None     Source Type: Journal    
DOI: 10.1023/B:NEON.0000021824.41701.e5     Document Type: Article

References (39)

1. Russell DS, Rubinstein LJ: Pathology of Tumors of the Central Nervous System. Williams and Wilkins, 1989, pp. 251-279
2. Tomlinson FH, Scheithauer BW, Meyer FB, Smithson WA, Shaw EG, Miller GM, Groover RV: Medulloblastoma. I. Clinical, diagnostic, and therapeutic overview. J Child Neurol 7: 142-155, 1992
3. Schlag P: Regional chemotherapy: different operative techniques and clinical results. Cancer Treat Rev 17: 183-189, 1990
4. Newton HB: Review of the molecular genetics an chemotherapeutic treatment of adult and pediatric medulloblastoma. Expert Opion. Invest. Drugs 10: 2090-2105, 2001
5. Trojanowski JQ, Tohyama T, Lee VMY: Medulloblastomas and related primitive neuroectodermal brain tumors of childhood recapitulate molecular milestone in the maturation of neuroblasts. Mol Chem Neuropathol 17: 121-135, 1992
6. Segal RA, Goumnerrova LC, Kwon YK, Stiles CD, Pomeroy SL: Expression of neurotrophin receptor TrkC is linked to a favorable outcome in medulloblastoma. Proc Natl Acad Sci USA 91: 12867-12871, 1994
7. Koxmik Z, Sure U, Rüedi D, Busslinger M, Aguzzi A: Deregulated expression of PAX5 in medulloblastoma. Proc Natl Acad Sci USA 92: 5709-5713, 1995
8. Yokota Z, Aruga J, Takai S, Yamada K, Hamazaki M, Iwase T, Sugimura H, Mikoshiba K: Predominant expression of human zic in cerebellar granule cell lineage and medulloblastoma. Cancer Res 56: 377-383, 1996
9. Washiyama K, Muragaki Y, Rorke LB, Lee VMY, Feinstein SC, Radeke MJ, Blumberg D, Kaplan DR, Trojanowski JQ: Neurotrophin and neurotrophin receptor proteins in medulloblastomas and other primitive neuroectodermal tumors of the pediatric central nervous system. Am J Pathol 148: 929-940, 1996
10. Rostomily RC, Bermingham-McDonogh O, Berger MS, Tapscott SJ, Reh TA, Olson JM: Expression of neurogenic basic helix-loop-helix genes in primitive neuroectodermal tumors. Cancer Res 57: 3526-3531. 1997
11. Gilbertson RL, Clifford SC, MacMeekin W, Wright C, Perry RH, Kelly P, Pearson ADJ, Lunec J. Expression of ErbB-neuregulin signalling network during human cerebellar development: implications for biology of medulloblastoma. Cancer Res 58: 3932-3941, 1998
12. Iantosca MR, McPherson CE, Ho S-Y, Maxwell GD: Bone morphogenic proteins-2 and -4 attenuate apoptosis in a cerebellar primitive neuroectodermal tumor cell line. J Neurosci Res 56: 248-258, 1999
13. Kenigsberg RL, Hong Y, Yao H, Lemieux N, Michaud J, Tautu C, Théorêt Y: Effects of basic fibroblast growth factor on the differentiation, growth an viability of a new human medulloblastoma cell line (UM-MB-1). Am J Pathol 151: 867-881, 1997
14. Duplan SM, Théorêt Y, Kenigsberg RL: Antitumor activity of fibroblast growth factors (FGFs) for medulloblastoma may correlate with FGF receptor expression and tumor variant. Clin Cancer Res 8: 246-257, 2002
15. Segal RH, Takahashi H, McKay RDG: Changes in neurotrophin responsiveness during the development of cerebellar granule neurons. Neuron 9: 1041-1052, 1992
16. Segal RA, Pomeroy SL, Stiles CD: Axonal growth and fasciculation linked to differential expression of BDNF and NT3 receptors in developing cerebellar granule cells. J Neurosci 15: 4970-4981, 1995
17. Huber H, Eggert A, Janss AJ, Wiewrodt R, Zhao H, Sutton LN, Rorke LB, Phillips PC, Grotzer MA: Angiogenic profile of childhood primitive neuroectodermal brain tumors/medulloblastomas. Eur J Cancer 37: 2064-2072, 2001
18. Pavlakovic H, Von Schutz V, Rossler J, Koscielniak E, Havers W, Schweigerer L: Quantification of angiogenesis stimulators in children with solid malignancies. Int J Cancer 92: 756-760, 2001
19. Vachon P, Kenigsberg RL, Moghrabi A, Tautu C, Lemieux N, Michaud Y, Théorêt Y: Effects of basic fibroblast growth factor (bFGF) on human medulloblastoma (MB) xenografts. J Ped Hematol Oncol 21: 321, 1999
20. Friedman HS, Burger PC, Bigner SH, Tojanowski JQ, Wirkstrand CJ, Halperin EC, Bigner DD: Establishment and characterization of the human cell line and transplantable xenograft D283. J Neuropath Exp Neurol 44: 592-605, 1985
21. Friedman HS, Burger PC, Bigner SH, Tojanowski JQ, Brodeur GM, HE X, Kurtzberg J, Berens ME, Halperin EC, Bigner DD: Phenotypic and genotypic analysis of a human medulloblastoma cell line and transplantable xenograft (D341Med) demonstrating amplification of c-myc. Am J Pathol 130: 472-484, 1988
22. Colin S, Jeanny J-C, Mascarelli F, Vienet R, Al-Marmood S, Courtois Y, Labarre J: In vivo involvement of heparan sulfate proteoglycan in the bioavailability, internalisation an catabolism of exogenous basic fibroblast growth factor. Mol Pharm 1: 74-82, 1999.
23. Edelman ER, Nugent M, Karnovsky M: Perivascular and intravenous administration of basic fibroblast growth factor: vascular and solid organ deposition. Proc Natl Acad Sci USA 90: 1513-1517, 1993
24. Lazarous DF, Shou M, Stiber JA, Dadhania DM, Thirumurti V, Hodge E, Unger EF: Pharmacodynamics of basic fibroblast growth factor: route of administration determines myocardial and systemic distribution. Cardiovasc Res 36: 78-85, 1997
25. Yuge T, Furukawa A, Nakamura K, Nagashima Y, Shinozaki K, Nakamura T, Kimura R: Metabolism of the intravenous administered recombinant human basic fibroblast growth factor, transferrin, in the liver and kidney: degradation implicated in irs selective localization to the fenestrated type microvasculatures. Biol Pharm Bull 20: 786-793, 1997
26. Degushi Y, Naito T, Yuge T, Furukawa A, Yamada S, Pardridge WM, Kimura R: Blood-brain barrier transport of 1251-labeled basic fibroblast growth factor. Pharm Res 17: 63-69, 2000
27. Bush MA, Samara E, Whitehouse MJ, Yoshizawa C, Novicki DL, Pike M, Laham RJ, Simons M, Chronos NA: Pharmacokinetics and pharmacodynamics of recombinant FGF-2 in a Phase I trial in coronary artery disease. J Clin Pharmacol 41: 378-385, 2001
28. Lazarous DF, Unger EF, Epstein SE, Stine A, Arevalo JL, Chew EY, Quyyumi AA : Basic fibroblast growth factor in patients with intermittent claudication. Results of Phase I trial. J Am Coll Cardiol 36: 1239-1244, 2000
29. Wu D, Song BW, Vinters HV, Pardridge WM: Pharmacokinetics and brain uptake of biotinylated basic fibroblast growth factor conjugated to a blood-brain barrier drug delivery system. J Drug Target 10: 239-245, 2002
30. Song BW, Vinters HV, Wu D, Pardridge WM: Enhanced neuroprotective effects of basic fibroblast growth factor in regional brain ischemia after conjugation to a blood-brain barrier delivery vector. J Pharmacol Exp Therap 301: 605-610, 2002
31. Élie I, Carpentier A, Delattre J-Y: Actualités en neurooncologie. Bull Cancer 89: 131-137, 2002
32. Weil MD: Primitive neuroectodermal tumors/medulloblastoma. Curr Neurol Neurosci Rep 2: 205-209, 2002
33. Gonzalez AM, Buscaglia ML, Fuller J, Dahl R, Carman LS, Baird A: Local fate and distribution of locally infused basic FGF. Ann NY Acad Sci 638: 416-419, 1991
34. Collins JM: Pharmacologic rational for regional drug delivery. J Clin Oncol 2: 498-504, 1984
35. Tomita T: Interstitial chemotherapy for brain tumors: review. J Neuro-Oncol 10: 57-74, 1991
36. Pulfer SK, Ciccotto SL, Gallo JM: Distribution of small magnetic particles in brain tumor-bearing rats. J Neuro-Oncol 41: 99-105, 1999
37. Bakhshi S, North RB: Implantable pumps for drug delivery to the brain. J Neuro-Oncol 26: 133-139, 1995
38. Buahin KG, Brem H: Interstitial chemotherapy of experimental brain tumors: comparison of intratumoral injection versus polymeric controlled release. J Neuro-Oncol 26: 103-110, 1995
39. Brem H, Mahaley MS, Vick NA, Black KL, Schold SC, Eller TW, Cozzen JW, Kenealy JN: Interstitial chemotherapy with drug polymer implants for the treatment of recurrent gliomas. J Neurosurg 74: 441-446, 1991